Evidence from preclinical and clinical studies supports their active involvement in MS pathogenesis, strengthening the concept of MS as a predominantly T cell-mediated disease and paving the way for future development of CD20+ T cells as a biomarker of MS activity and treatment response. Here, MS4A1 is linked to myeloid sarcoma.